

ONE HUNDRED NINETEENTH CONGRESS

Congress of the United States
House of Representatives

COMMITTEE ON THE JUDICIARY

2138 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6216

(202) 225-6906
judiciary.house.gov

May 15, 2025

Dr. Albert Bourla
Chairman and Chief Executive Officer
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

Dear Dr. Bourla:

On March 26, 2025, the *Wall Street Journal* reported that authorities were in possession of information that originated from a former senior Pfizer executive related to whether Pfizer “sat on the positive results of clinical trials” of its COVID-19 vaccine so as to influence the 2020 presidential election.¹ The *Journal* identified Dr. Philip Dormitzer as the former Pfizer executive, and reported that he disclosed this information to his then-current employer, GSK plc, in “late 2024” following President Trump’s election.²

In response to these allegations, on April 9, 2025, the Committee wrote to GSK requesting further information about these allegations.³ GSK responded on April 16, 2025.⁴ In its letter to the Committee, GSK stated:

In November 2024, shortly after the election, Dr. Dormitzer approached a representative from the GSK human resources team to speak about a potential relocation abroad. As the human resources representative recalls, in their meeting, Dr. Dormitzer was visibly upset; he requested that he be relocated to Canada due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer’s COVID-19 vaccine. According to the human resources representative, when asked what prompted his request, Dr. Dormitzer

¹ Josh Dawsey, Gregory Zuckerman, & Jared S. Hopkins, *U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine*, Wall St. J. (March 26, 2024) <https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247>.

² *Id.*

³ Letter from Rep. Jim Jordan, Chairman, H. Comm. on the Judic., to Emma Walmsley, Chief Executive Officer, GSK plc. (Apr. 9, 2025).

⁴ Letter from Reginald J. Brown, Kirkland & Ellis LLP, to Rep. Jim Jordan, Chairman, H. Comm. On the Judic., (Apr. 16, 2025).

made a comment to the effect of: “Let’s just say it wasn’t a coincidence, the timing of the vaccine.”⁵

GSK further informed the Committee that **Dr. Dormitzer had told GSK employees that “in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year.”**⁶ GSK alleged that “Dr. Dormitzer was clear that this was not a situation of delaying disclosure of completed results but was a situation of slowing down results before disclosure became necessary.”⁷

This new information appears to suggest that Dr. Dormitzer and other senior Pfizer executives conspired to withhold public health information to influence the 2020 presidential election. Due to the seriousness of these allegations, the Committee is compelled to request additional information to inform our oversight. We request that you produce the following material:

1. All documents and communications, including but not limited to emails, text messages, and meeting notes, between or among Pfizer employees or representatives referring or relating to the reporting of data from Pfizer’s COVID-19 vaccine clinical testing for the period March 1, 2020, to the present;
2. All documents and communications between or among Pfizer employees and executive branch agencies, including but not limited to the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the Department of Health and Human Services (HHS), referring or relating to the clinical testing of Pfizer’s COVID-19 vaccine for the period March 1, 2020, to the present; and
3. All documents and communications sent or received by Dr. Philip Dormitzer referring or relating to the reporting of data from Pfizer’s COVID-19 vaccine clinical testing for the period March 13, 2020, to November 30, 2021.

Please provide the requested documents and information as soon as possible but no later than 10:00 a.m. on May 29, 2025. Pursuant to the Rules of the House of Representatives, the Committee on the Judiciary has jurisdiction to conduct oversight of matters concerning civil liberties and “administrative practice and procedures” to inform potential legislative reforms.⁸

⁵ *Id.* at 2.

⁶ *Id.* (emphasis added).

⁷ *Id.* at 2-3.

⁸ Rules of the House of Representatives R. X.

Dr. Albert Bourla

May 15, 2025

Page 3

If you have any questions about this matter, please contact Committee staff at (202) 225-6906. Thank you for your attention to this important matter.

Sincerely,

A handwritten signature in blue ink that reads "Jim Jordan". The signature is fluid and cursive, with the first name "Jim" and last name "Jordan" clearly distinguishable.

Jim Jordan
Chairman

cc: The Honorable Jamie Raskin, Ranking Member